Compare BRKR & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRKR | GKOS |
|---|---|---|
| Founded | 1960 | 1998 |
| Country | United States | United States |
| Employees | 11085 | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 6.0B |
| IPO Year | 2000 | 2015 |
| Metric | BRKR | GKOS |
|---|---|---|
| Price | $40.97 | $123.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 12 |
| Target Price | $48.54 | ★ $126.92 |
| AVG Volume (30 Days) | ★ 1.6M | 650.9K |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.49% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,895,600,000.00 | $507,442,000.00 |
| Revenue This Year | $6.30 | $23.32 |
| Revenue Next Year | $3.81 | $27.43 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 32.33 |
| 52 Week Low | $28.53 | $73.16 |
| 52 Week High | $56.22 | $130.23 |
| Indicator | BRKR | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 65.39 | 65.45 |
| Support Level | $35.45 | $81.54 |
| Resistance Level | $41.29 | $130.23 |
| Average True Range (ATR) | 1.45 | 4.45 |
| MACD | 0.62 | 1.26 |
| Stochastic Oscillator | 98.76 | 85.64 |
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies (BEST) . The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.